This perspective was first shared in our Weekly View e-newsletter, which summarizes the week’s most significant drug pricing news. To subscribe, click here

NICE announced a collaboration with ICER, CADTH, and ZIN (also known as the National Healthcare Institute in the Netherlands) to share learnings about the development of economic models at the disease level (rather than product level).

NICE stated: “Reference models span a disease pathway and can be used to assess multiple technologies across the pathway. The group is also providing a simple way for organisations to exchange information, share developed pathway models, discuss best practice, give feedback, and overcome any technical and administrative issues.” Learn more about the initiative here.